Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: CapitalistHogg™ who wrote (22769)	12/17/2005 2:10:50 PM
From: Suma	Read Replies (2) \| Respond to of 78748

I was utilizing the services of a broker who was a son of one of my friends.He worked for Steifel &Coompany out of MN. He put me in three stocks which lost me a lot of money. VASC,NPTH VISG and MTIC.ob. I have kept all of them on my radar to view. VASC does have anew product and the stock is moving up. In fact all three stocks are moving. If you put VASC in Yahoo quotes you can check on the news about it when the quote comes up. I also follow some of what those who own it are messaging... Good luck. Oh, he had me in one good one. CNXS but sold too soon.

To: CapitalistHogg™ who wrote (22769)	12/17/2005 7:54:03 PM
From: gcrispin	Read Replies (1) \| Respond to of 78748

In my opinion, VASC has longer term problems as their thrombin is bovine-based. Below is a quote from an article I posted on the SI VASC, asking for comments. A new type of thrombin could quickly render the older molecule obsolete. King's Thrombin-JMI is derived from the blood of cows. Even after a rigorous purification process, it contains some additional cow-based proteins that occasionally cause allergic reactions in patients. In rare cases, patients can become anemic, complicating their recovery from whatever procedure called for thrombin in the first place. "[Patients] can have antibodies to bovine-based thrombin, and that can lead to significant bleeding disorders," says Alvin Schmaier, a hematologist at the University of Michigan. "Even with purification from cow blood or human blood, you can still have contaminating proteins, so the best kind of agent to use would be a recombinant one." Recombinant is pharmaceutical-speak for genetically engineered. Zymogenetics (ZGEN4), a Seattle-based biotech, is trying to create the first recombinant thrombin, called rhThrombin. Analysts say that unlike King's version of the drug, rhThrombin might not require a black-box warning on the label, the FDA's most stringent caution of a drug's potential side effects. Edward Tenthoff, an analyst with Piper Jaffray in Minneapolis, is optimistic that there won't be a black-box warning. "This will be an important competitive advantage against Thrombin-JMI," he wrote in an August research note. "As a result, we expect Zymo will rapidly convert the surgical bleeding market, which we estimate could reach $300 million by the time rhThrombin is approved [in 2007]."